Oral Squamous Cell Carcinoma (OSCC) Imitates Denosumab-Induced Osteonecrosis of the Mandibular Alveolus: A Diagnostic Challenge.
denosumab and cancer
jaw osteonecrosis
medication-related osteonecrosis of the jaw
oral cancers
oral cavity squamous cell carcinoma
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
28
07
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) may arise in the the alveolar ridge (in a minority of cases). Smoking, chronic mucosal injuries, and poor oral hygiene are involved in its pathogenesis. It mostly occurs to men instead of women and affects the mandible on a 3:2 ratio to the maxilla. The objective of the current study is to present an interesting case of an OSCC of the alveolar ridge mimicking jaw osteonecrosis due to denosumab, resulting in differential diagnostic dilemmas. A 78-year-old female patient, edentulous and bearing total dentures, was referred with a persistent (four months), severely painful, ulcerative lesion in the anterior lateral (right) region of the residual alveolar ridge of the mandible. Medical history referred to a long-term systemic steroid use due to sarcoidosis as well as the subcutaneous use of denosumab for osteoporosis one/month for one year. Cone-beam CT (CBCT) examination was performed where bone resorption was detected and a differential diagnosis of osteonecrosis of the jaws (ONJs) from denosumab or neoplasia was made. A biopsy was carried out, and the histological examination showed that soft tissues and underlying bone were infiltrated by abnormal, confluent, compact islands of malignant squamous cells with intense atypia and numerous mitoses indicating a moderately differentiated OSCC. Denosumab inhibits the binding of receptor activator of nuclear factor ligand (RANKL) to receptor activator of nuclear factor-kappa (RANK); this decreases bone resorption and results in increased bone density. However, denosumab may induce ONJ. The area of exposed bone and abnormal soft tissue alterations may resemble both benign and malignant diseases. Osteonecrosis may mimic OSCC or may even provide the suitable substrate for the development of OSCC. Biopsy as well as bone imaging examination are required to accurately determine the possibility of neoplastic formation and its boundaries in cases of osteonecrosis especially in patients under treatment with denosumab or bisphosphonate-related ONJ (BRONJ).
Identifiants
pubmed: 37565127
doi: 10.7759/cureus.42619
pmc: PMC10410184
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e42619Informations de copyright
Copyright © 2023, Zisis et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
Front Cell Dev Biol. 2021 Aug 05;9:687245
pubmed: 34422810
Saudi Med J. 2016 Mar;37(3):249-55
pubmed: 26905345
Clin Oral Implants Res. 2016 Mar;27(3):367-75
pubmed: 25639776
Ann Med Surg (Lond). 2020 Oct 20;60:195-200
pubmed: 33163176
Oral Oncol. 2018 Dec;87:64-69
pubmed: 30527245
Br J Oral Maxillofac Surg. 2017 Nov;55(9):e53-e57
pubmed: 28851496
Br Dent J. 2007 Jul 28;203(2):87-9
pubmed: 17660778
Semin Musculoskelet Radiol. 2016 Jul;20(3):305-314
pubmed: 27741546
Case Rep Dent. 2015;2015:831418
pubmed: 25973278
J Oral Pathol Med. 2012 Jan;41(1):34-9
pubmed: 21902722
J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):233-47
pubmed: 23040351
Oncol Lett. 2017 Jul;14(1):127-136
pubmed: 28693144
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11884-94
pubmed: 26617944
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Chin J Cancer. 2013 Nov;32(11):614-8
pubmed: 23601241